Efficient expression of a transgene in platelets using simian immunodeficiency virus‐based vector harboring glycoprotein Ibα promoter:in vivomodel for platelet‐targeting gene therapy
- 24 May 2006
- journal article
- Published by Wiley in The FASEB Journal
- Vol. 20 (9) , 1522-1524
- https://doi.org/10.1096/fj.05-5161fje
Abstract
Platelets release several mediators that modify vascular integrity and hemostasis. In the present study, we developed a technique for efficient transgene expression in platelets in vivo and examined whether this targeted-gene-product delivery system using a platelet release reaction could be exploited for clinical applications. Analysis of luciferase reporter gene constructs driven by platelet-specific promoters (the GPIIb, GPIbalpha, and GPVI) revealed that the GPIbalpha promoter was the most potent in the megakaryoblastic cell line UT-7/TPO and human CD34+-derived megakaryocytes. Transduction of UT-7/TPO; CD34+-derived megakaryocytes; and c-Kit+, ScaI+, and Lineage- (KSL) murine hematopoietic stem cells with a simian immunodeficiency virus (SIV)-based lentiviral vector carrying eGFP resulted in efficient, dose-dependent expression of eGFP, and the GPIbalpha promoter seemed to bestow megakaryocytic-specific expression. Transplantation of KSL cells transduced with SIV vector containing eGFP into mice showed that there was preferable expression of eGFP in platelets driven by the GPIbalpha promoter [7-11% for the cytomeglovirus (CMV) promoter, 16-27% for the GPIbalpha promoter]. Furthermore, transplantation of ex vivo-transduced KSL cells by SIV vector carrying human factorVIII (hFVIII) driven by the GPIbalpha promoter induced the production of detectable transcripts of the hFVIII gene and the hFVIII antigen in bone marrow and spleen for at least 90 days and partially corrected the hemophilia A phenotype. Platelet-targeting gene therapy using SIV vectors appears to be promising for gene therapy approaches toward not only inherited platelet diseases but also other hemorrhagic disorders such as hemophilia A.Keywords
Funding Information
- Ministry of Education and Science
- Ministry of Education, Culture, Sports, Science and Technology
This publication has 34 references indexed in Scilit:
- Therapeutic expression of the platelet-specific integrin, IIb 3, in a murine model for Glanzmann thrombastheniaBlood, 2005
- Sustained transgene expression by human cord blood derived CD34+ cells transduced with simian immunodeficiency virus agmTYO1‐based vectors carrying the human coagulation factor VIII gene in NOD/SCID miceThe Journal of Gene Medicine, 2004
- Induction of immune tolerance by neonatal intravenous injection of human factor VIII in murine hemophilia AJournal of Thrombosis and Haemostasis, 2004
- Induction of megakaryocytes to synthesize and store a releasable pool of human factor VIIIJournal of Thrombosis and Haemostasis, 2003
- Factor VIII ectopically expressed in platelets: efficacy in hemophilia A treatmentBlood, 2003
- Antithrombotic thrombocytes: ectopic expression of urokinase-type plasminogen activator in plateletsBlood, 2003
- Molecular Basis of Platelet Granule SecretionArteriosclerosis, Thrombosis, and Vascular Biology, 2003
- A Serious Adverse Event after Successful Gene Therapy for X-Linked Severe Combined ImmunodeficiencyNew England Journal of Medicine, 2003
- Recombinant adeno-associated virus vector-transduced vascular endothelial cells express the thrombomodulin transgene under the regulation of enhanced plasminogen activator inhibitor-1 promoterGene Therapy, 2001
- Development of Novel Simian Immunodeficiency Virus Vectors Carrying a Dual Gene Expression SystemHuman Gene Therapy, 2000